Spectrum Pharmaceuticals, Inc.

Pharma Mar, S.a.

Pharma Mar, S.a., Sociedad Unipersonal

Stichting Het Nederlands Kanker Instituut

Slotervaart Participaties Bv

Bastiaan Nuijen

Ernie Pfadenhauer

Jacob Hendrik Beijnen

Jos H Beijnen

Guru Reddy

Luigi Lenaz

Dorla Mirejovsky

Pilar Calvo Salve

Maria Tobio Barreira

Glynn Thomas Faircloth

Jose Jimeno

Steve Weitman

Johannes Henricus Matthias Schellens

Johannes Jan Moes

Jos H Beijen

Roland Elizabeth Cornelis Henrar

Andres Gomez

Johannes Moes

Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.

Pharmaceutical formulations of ecteinascidin compounds

Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Bladder cancer treatment and methods

Pharmaceutical compositions and methods for the treatment of neoplastic disease and comprising the combination of a taxane, such as docetaxel, with a CYP3A4 inhibitor, such as ritonavir. Methods of treatment of neoplastic disease incorporating the administration of a taxane and the administration of a CYP3A4 inhibitor, either simultaneously or separately, are also included. Further, kits for carrying out the methods are included. Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant are also included.

Composition

Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Medical compositions for intravesical treatment of bladder cancer

A stable pharmaceutical composition of a didemnin compound, comprises firstly a lyophilized didemnin preparation including water-soluble material and secondly a reconstitution solution of mixed solvents.

Pharmaceutical formulation of a didemnin compound

Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.

Kahalalide F

Growing community of inventors

Amsterdam, Netherlands

Bastiaan Nuijen